Compass Pathways Remains on Track for COMP360 Launch Following Q3 Results, RBC Says MT Nov. 03 COMPASS Pathways plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in ...

An accelerated FDA review could benefit Compass Pathways.

Compass Pathways (CMPS) stock rebounds after Q3 results calm launch fears over psilocybin compound COMP360 as Usona completes ...

COMPASS Pathways has seen sharp moves in its share price over recent years, and that volatility now raises a straightforward ...

Its clinic network of more than 8,500 interventional psychiatry centers gives COMP360 a ready path to patients once approved.

Olivia Goldhill focused primarily on covering the health crisis affecting American boys and men. She also covered psychedelic medicines. Compass Pathways said Monday it achieved its primary endpoint ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

COMPASS Pathways (CMPS) drew fresh attention after confirming a prominent role at the 2026 NEI Fall Congress, highlighting ...

Current-quarter investor focus broadened from FDA guidance interpretation and rescheduling cadence (Q2) to granular execution items (CPT code transition "12 to 18 months," REMS training "1 to 2 hours, ...

Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 partici ...